Sarah Herterich

Sarah Herterich

Auto-generated profile, based on publicly available information

Sarah Herterich

Tubulis GmbH, Planegg, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SSSaskia Schmitt
Saskia Schmitt
PMPaul Machui
Paul Machui
IMIsabelle Mai
Isabelle Mai
SHSarah Herterich
Sarah Herterich
SWSwetlana Wunder
Swetlana Wunder
MKMarc-André Kasper
Marc-André Kasper
Topoisomerase I (TOP1) Inhibitors constitute an emerging payload class to engineer antibody–drug conjugates (ADC) as next-generation biopharmaceutical for cancer treatment. Existing ADCs are using camptothecin payloads with lower potency and suffer from limited stability in circulation. With this study, we introduce a novel camptothecin-based linker–payload platform based on the highly potent camptothecin derivative exatecan. First, we describe general challenges that arise from the hydrophobic combination of exatecan and established dipeptidyl p-aminobenzyl-carbamate (PAB) cleavage sites such as reduced antibody conjugation yields and ADC aggregation. After evaluating several linker–payload structures, we identified ethynyl-phosphonamidates in combination with a discrete PEG24 chain to compensate for the hydrophobic PAB–exatecan moiety. Furthermore, we demonstrate that the identified linker–payload structure enables the construction of highly loaded DAR8 ADCs with excellent solubility properties. Head-to-head comparison with Enhertu, an approved camptothecin-based ADC, revealed improved target-mediated killing of tumor cells, excellent bystander killing, drastically improved linker stability in vitro and in vivo and superior in vivo efficacy over four tested dose levels in a xenograft model. Moreover, we show that ADCs based on the novel exatecan linker–payload platform exhibit antibody-like pharmacokinetic properties, even when the ADCs are highly loaded with eight drug molecules per antibody. This ADC platform constitutes a new and general solution to deliver TOP1 inhibitors with highest efficiency to the site of the tumor, independent of the antibody and its target, and is thereby broadly applicable to various cancer indications.

16 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
AVAnnette M. Vogl
Annette M. Vogl
SSSaskia Schmitt
Saskia Schmitt
IMIsabelle Mai
Isabelle Mai
PMPaul Machui
Paul Machui
SHSarah Herterich
Sarah Herterich
JHJonas Helma
Jonas Helma
TUB-040 is a highly homogeneous and hydrophilic antibody–drug conjugate (ADC) targeting sodium-dependent phosphate transport protein 2b (NaPi2b), a surface receptor overexpressed in ovarian cancer and non–small cell lung adenocarcinoma. Previous NaPi2b-directed therapies have shown target-mediated and expression-dependent clinical activity. However, none of the previous tubulin inhibitor-based ADCs have been able to leverage the full therapeutic potential of the target. TUB-040 was constructed with a drug-to-antibody ratio of 8 using the Tubutecan linker-payload technology based on ethynylphosphonamidates (P5 conjugation chemistry), a protease cleavage site, and exatecan, a potent topoisomerase 1 inhibitor. TUB-040 induces potent antigen-specific cytotoxicity against NaPi2b-expressing cancer cells and demonstrates strong bystander activity. It displays favorable pharmacokinetic behavior, showing dose proportionality and superimposable total antibody and intact ADC curves, as well as low free payload levels, reflecting the high stability of TUB-040 enabled by the P5 conjugation platform. This specific feature also ensures sustained delivery of exatecan to tumor sites, which translates into excellent in vivo efficacy and tolerability. In cell line– and patient-derived xenograft models, including those with low target expression, single-dose TUB-040 administration leads to prolonged tumor growth inhibition and significant rates of complete remission, with a minimally effective dose level of 1 mg/kg in the OVCAR-3 model. Repeated-dose toxicologic assessment in rats indicates that TUB-040 is well tolerated, with no evidence of lung toxicity or thrombocytopenia. Taken together, TUB-040 is designed to enable long-lasting, durable tumor responses and to optimize both efficacy and tolerability, supporting the advancement of TUB-040 into clinical trials.

3 November 2025
Verified
Other
Open access
AVAnnette M. Vogl
Annette M. Vogl
SSSaskia Schmitt
Saskia Schmitt
IMIsabelle Mai
Isabelle Mai
PMPaul Machui
Paul Machui
SHSarah Herterich
Sarah Herterich
JHJonas Helma
Jonas Helma
Supplementary Figure 5 shows cross-reactivity of TUB-040 to cynomolgus and rat NaPi2b

1 February 2024
Verified
Other
Open access
SSSaskia Schmitt
Saskia Schmitt
PMPaul Machui
Paul Machui
IMIsabelle Mai
Isabelle Mai
SHSarah Herterich
Sarah Herterich
SWSwetlana Wunder
Swetlana Wunder
MKMarc-André Kasper
Marc-André Kasper
Characterization Data on the antibodies and antibody-drug-conjugates.

1 February 2024
Verified
Other
Open access
SSSaskia Schmitt
Saskia Schmitt
PMPaul Machui
Paul Machui
IMIsabelle Mai
Isabelle Mai
SHSarah Herterich
Sarah Herterich
SWSwetlana Wunder
Swetlana Wunder
MKMarc-André Kasper
Marc-André Kasper
Dose-response curves for the ADC synthesized from trastuzumab and LP1 and LP3-LP3 on SKBR-3, HCC-78 and MDA-MB-468

1 February 2024
Verified
Other
Open access
SSSaskia Schmitt
Saskia Schmitt
PMPaul Machui
Paul Machui
IMIsabelle Mai
Isabelle Mai
SHSarah Herterich
Sarah Herterich
SWSwetlana Wunder
Swetlana Wunder
MKMarc-André Kasper
Marc-André Kasper
Analytical SEC chromatograms of trastuzumab-LP3 DAR8, trastuzumab-LP5 DAR8 and Enhertu at day 0 and after storage for four weeks at 4°C and 37°C in the dark.